B+
Bull case
25%
Probability
Target price
$1.45
+55.7% vs current
CGC
Canopy GrowthBNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-08-04
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
45%
Probability
Target price
$1.10
+18.1% vs current
B-
Bear case
30%
Probability
Target price
$0.60
-35.6% vs current
AI sentiment snapshot
Latest data as of 2026-06-25
Recent news sentiment (30D)
+58.0
Positive
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Sentiment proxy
+71.6
Score
AI commentary
June 2026 news flow improved after the June 15, 2026 results release, with primary company materials emphasizing revenue growth, medical and international momentum, net cash, and an FY2027 EBITDA objective [#SEC-8K-2026-06-15]. The peer framing is better anchored to direct cannabis names than the generic biotech screen, but post-print price-reaction, analyst-revision evidence, and detailed peer operating evidence are not available in the packet, so this remains a cautious monitoring setup rather than a standard-conviction sentiment breakout call.
RankAlpha Sentiment Codex - 2026-06-25
Open full AI memoEvidence flagged
small-cap biotech peer set is too weak or includes unrelated comparators for a standard-conviction report
Impact
tentative
Confidence
-
AI events
2026-09-30eventNext few quarters need to convert medical and international growth into cleaner reported marginsHigh impact
Q4 FY2026 revenue growth was strongest in Canada medical and international cannabis, but reported profitability still carried acquisition and inventory-related noise; the next reported quarters need to show whether MTL integration and mix improvement can translate into visibly better margins and narrower losses [#SEC-8K-2026-06-15].
2027-03-31catalystFY2027 positive Adjusted EBITDA target is the main rerating testHigh impact
Management said the company enters fiscal 2027 with momentum and has the strategy and financial model to achieve positive Adjusted EBITDA during fiscal 2027, making execution against that profitability target the clearest long-duration catalyst [#SEC-8K-2026-06-15].
2027-03-31catalystBalance-sheet improvement lowers financing stress but must holdHigh impact
Canopy ended fiscal 2026 with net cash of $131.3M after recapitalization, which reduces near-term financing pressure; sustaining that runway while moving toward EBITDA breakeven would support the equity, while renewed burn or dilution risk would likely pressure shares [#SEC-8K-2026-06-15].
Recommendation
N/A
No formal recommendation provided.
As of 2026-06-25 • Updated nightlySource: Internal modelMethodology